Aubagio, whose generic name is teriflunomide, is a medication prescribed for people with relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS and active secondary progressive MS. It is an oral disease-modifying therapy designed to slow the progression of MS and reduce the frequency of relapses. While it does not cure MS, Aubagio offers several important benefits that can improve the quality of life for those living with this chronic neurological condition.
One of the primary benefits of Aubagio is its ability to **reduce the number of relapses** in people with relapsing MS. Relapses are episodes where symptoms suddenly worsen or new symptoms appear, often leading to increased disability. By decreasing the frequency of these relapses, Aubagio helps to stabilize the disease course and prevent the accumulation of disability over time. This effect is crucial because fewer relapses mean less inflammation and damage to the nervous system.
Aubagio works by **modulating the immune system**, specifically targeting the activity of certain white blood cells called lymphocytes. These cells are involved in the autoimmune attack on the nervous system that characterizes MS. By selectively interfering with lymphocyte function, Aubagio reduces the immune system’s ability to cause inflammation and nerve damage, which are responsible for MS symptoms and progression. This targeted approach helps to control the disease while minimizing widespread immune suppression.
Another significant benefit is that Aubagio is taken orally as a once-daily tablet, which many patients find more convenient compared to injectable or infusion therapies. This ease of administration can improve adherence to treatment, which is essential for maintaining its effectiveness over time. The oral route also avoids the discomfort and complications sometimes associated with injections.
Aubagio has been shown to **slow some disabling effects** of MS. While it does not reverse existing damage, it can help prevent new damage by controlling disease activity. This slowing of disability progression means patients may maintain their mobility, cognitive function, and independence for longer periods.
In terms of safety and tolerability, Aubagio is generally well tolerated, though it can have side effects. Some patients experience mild hair thinning or temporary hair loss, which usually resolves without stopping the medication. Other potential side effects include gastrointestinal symptoms, elevated liver enzymes, and increased risk of infections. Because Aubagio affects the immune system, patients are advised to avoid live vaccines during treatment and to be cautious about infections. Regular monitoring by a healthcare provider is important to manage these risks effectively.
Aubagio also has a long half-life, meaning it stays in the body for an extended period after stopping treatment. This characteristic requires careful planning around vaccinations and any potential pregnancy, as the drug can affect fetal development. Patients are typically advised to undergo specific procedures to accelerate drug elimination if they need to discontinue it quickly.
Overall, Aubagio offers a balance of **efficacy, convenience, and manageable safety** for many people with relapsing MS. It helps reduce relapses, slows disability progression, and is easy to take, making it a valuable option in the range of disease-modifying therapies available today. Its immune-modulating action targets the underlying disease process, aiming to protect the nervous system from ongoing damage and preserve function over time.
